EMA Recommends Granting a Marketing Authorisation for Glasdegib
Glasdegib, an Hedgehog inhibitor, is intended for the treatment of acute myeloid leukaemia
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves New Dosing Regimen for Pembrolizumab
Accelerated approval is based on data from the Cohort B of Study KEYNOTE-555
Kinase Fusions in ESR1 Wild-Type Metastatic Breast Cancer
Pathology analysis found enrichment of fusions after progression on endocrine therapy
First Results from the TERAVOLT Registry: mortality among thoracic cancer patients with COVID-19 is unexpectedly high
Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group
Withdrawal of Applications for the EU Marketing Authorisation of Rituximab Mabion
It was developed as a biosimilar medicine
Italian Researchers Report COVID-19 Modified Treatment Approaches in Patients with Hepatocellular Carcinoma
Treatment delay of at least 2 months reported in only one quarter of patients
FDA Approves Ibrutinib Plus Rituximab for Chronic Lymphocytic Leukaemia
Approval is based on the results from the E1912 trial
FDA Grants Accelerated Approval to Sacituzumab Govitecan-hziy for Metastatic TNBC
Efficacy in patients with metastatic triple negative breast cancer was demonstrated in IMMU-132-01 study
First Report on the Prognosis of COVID-19 Patients with Cancer in the US
An experience in New York City
FDA Approves Tucatinib for Patients with HER2-positive Metastatic Breast Cancer
Evidence for efficacy is based on the results from the HER2CLIMB trial
FDA Grants Accelerated Approval to Pemigatinib for Cholangiocarcinoma with an FGFR2 Rearrangement or Fusion
FDA also approved a companion diagnostic for patient selection
FDA Approves Selumetinib for Neurofibromatosis Type 1
It is approved for patients who have symptomatic, inoperable plexiform neurofibromas